LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial
Dimitri Henriques Daldegan-Bueno, C Donegan, Rachael Sumner, Anna Forsyth, Soo Hee Jeong, William Evans, Malak Alshakhouri, Robin J Murphy, Lisa Reynolds, Nicholas Hoeh, Nathan Allen, Frederick Sundram, David B Menkes, Suresh Muthukumaraswamy
Progress in Neuro-psychopharmacology and Biological Psychiatry February 18, 2026 DOI: 10.1016/j.pnpbp.2026.111645 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Clinical trial Peer reviewed |
|---|---|
| Population | People with depression |
| Intervention | LSD |
| Dose | 8 μg |
| Topics | Depression LSD Microdosing |
| Keywords | Pharmacokinetics Depression economics Depressive symptoms Clinical trial Sample material Clinical psychology Pharmacology Depressive mood Phase matter |
| Citations | 1 |
| Key findings | Short-term mood improvements followed microdosed LSD in people with depression, with no tolerance or sensitisation observed despite dose titration. |
Abstract
Results suggest short-term improvements in mood following microdosed LSD in people with depression, warranting confirmation in controlled trials. It provides the pharmacokinetic parameters of 8 μg of LSD in a sample of people with depression and indicates no tolerance or sensitisation to repeated microdoses of LSD, despite incremental dose titration.